<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329690</url>
  </required_header>
  <id_info>
    <org_study_id>DS8201-A-J202</org_study_id>
    <secondary_id>173727</secondary_id>
    <secondary_id>DESTINY-G01</secondary_id>
    <nct_id>NCT03329690</nct_id>
  </id_info>
  <brief_title>DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]</brief_title>
  <official_title>A Phase 2, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this trial is to compare the efficacy and safety of DS-8201a and&#xD;
      physician's choice treatment in HER2-overexpressing advanced gastric or gastroesophageal&#xD;
      junction adenocarcinoma patients who have progressed on two prior treatment regimens&#xD;
      including fluoropyrimidine agent, platinum agent, and trastuzumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Actual">December 11, 2020</completion_date>
  <primary_completion_date type="Actual">November 8, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two randomized investigative arms will run in parallel (DS-8201a and Physician's Choice), with participants who have disease progression after two previous regimens.&#xD;
Two non-randomized exploratory arms will run with HER2 treatment-naive participants.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Objective Response Rate Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</measure>
    <time_frame>Baseline to date of first documented objective response (CR or PR), up to 25 months postdose</time_frame>
    <description>The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by independent central imaging review (ICR) based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Unconfirmed ORR (not confirmed by ICR) and confirmed ORR (confirmed by ICR) are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</measure>
    <time_frame>Baseline to date of first documented objective response, up to 25 months postdose</time_frame>
    <description>The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by independent central imaging review (ICR) based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Unconfirmed BOR (not confirmed by ICR) and confirmed BOR (confirmed by ICR) are reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</measure>
    <time_frame>From the date of randomization to the date of death (due to any cause), up to 25 months postdose</time_frame>
    <description>Duration of survival follow-up (months) was defined as the date of last contact - date of randomization/ registration + 1.Overall Survival (OS) was defined as the time from the date of randomization (the date of the registration for the Exploratory Cohorts) to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</measure>
    <time_frame>From the date of randomization to the first documented disease progression or date of death (whichever occurs first), up to 25 months postdose</time_frame>
    <description>Progression-free survival (PFS) was defined as the time from the date of randomization (the date of the registration for the Exploratory Cohorts) to the earliest date of the first objective documentation of progressive disease (PD) or death due to any cause. PD was defined as at least a 20% increase in the sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Full Analysis Set)</measure>
    <time_frame>From the date of first objective response (CR or PR) to the date of first documentation of PD or death (whichever occurs first), up to 25 months postdose</time_frame>
    <description>Duration of Response (DOR) was defined as the time from the date of the first documentation of objective response (complete response [CR] or partial response [PR]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR was measured for responding subjects (PR or CR) only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate With and Without Confirmation by Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</measure>
    <time_frame>Baseline to date of first documented objective response (CR, PR, and SD), up to 25 months postdose</time_frame>
    <description>Disease control rate (DCR) was defined as the sum of complete response (CR) rate, partial response (PR) rate, and stable disease (SD) rate. As per RECIST v1.1, CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate and Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</measure>
    <time_frame>From randomization to first documented objective response, up to 25 months postdose</time_frame>
    <description>The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Independent Central Review (ICR) based on RECIST version 1.1. The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by Investigator based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions). Confirmed ORR and BOR (confirmed by ICR) are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Full Analysis Set)</measure>
    <time_frame>From date of randomization to first documentation of PD, death due to any cause, or treatment discontinuation (whichever comes first), up to 25 months postdose</time_frame>
    <description>Time to treatment failure (TTF) was defined as the time from the date of randomization (the date of the registration for Exploratory Cohorts) to the earliest date of the first objective documentation of progressive disease (PD), death due to any cause, or treatment discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate and Best Overall Response Based on Investigator Assessment Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Response Evaluable Set)</measure>
    <time_frame>From randomization to first documented objective response, up to 25 months postdose</time_frame>
    <description>The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Investigator based on RECIST version 1.1. The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by Investigator based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions). Unconfirmed ORR and BOR (not confirmed by Investigator) and confirmed ORR and BOR (confirmed by Investigator) are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter of Maximum Observed Serum Concentration (Cmax) and Trough Serum Concentration (Ctrough) of DS-8201a, Total Anti-HER2 Antibody, and MAAA-1181 Following Treatment With DS-8201a</measure>
    <time_frame>Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)</time_frame>
    <description>Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. The maximum serum concentration (Cmax) and the trough serum concentration (Ctrough) of DS-8201a were assessed. These serum PK parameters for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of Area Under the Concentration Versus-Time Curve of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a</measure>
    <time_frame>Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)</time_frame>
    <description>Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. Area under the concentration versus time curve (AUC) from Time 0 to the Last Quantifiable Concentration (AUClast) and Area Under the Concentration versus-Time Curve up to 21 days (AUC21d) are reported. These serum PK parameters for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter of Time to Maximum Serum Concentration (Tmax) of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a</measure>
    <time_frame>Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)</time_frame>
    <description>Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. The time to maximum serum concentration (Tmax) of DS-8201a was assessed. This serum PK parameter for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter Terminal Elimination Half-life (t1/2) of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a</measure>
    <time_frame>Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)</time_frame>
    <description>Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. Terminal elimination half-life (t1/2) of DS-8201a was assessed. This serum PK parameter for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Summary of Treatment-emergent Adverse Events (TEAEs) Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (Safety Analysis Set)</measure>
    <time_frame>Baseline up to 47 days after last dose, up to 25 months postdose</time_frame>
    <description>A treatment-emergent adverse event (TEAE) is defined as an adverse event that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the initiating the study drug until 47 days after last dose of the study drug. Serious adverse events (SAEs) with an onset or worsening 48 days or more after the last dose of study drug, if considered related to the study treatment, are also TEAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Most Common Treatment-Emergent Adverse Events (TEAEs) ≥20% of Any Grade by Preferred Term Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Safety Analysis Set)</measure>
    <time_frame>Baseline up to 47 days after last dose, up to 25 months postdose</time_frame>
    <description>A treatment-emergent adverse event (TEAE) is defined as an adverse event that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the initiating the study drug until 47 days after last dose of the study drug.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">233</enrollment>
  <condition>Neoplasm, Gastrointestinal</condition>
  <arm_group>
    <arm_group_label>Parallel: DS-8201a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive DS-8201a once every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parallel: Physician's Choice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive monotherapy prescribed by the physician before enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory: Naïve HER2 IHC 2+/ISH-</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A maximum of 20 non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory: Naïve HER2 IHC 1+</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A maximum of 20 non-randomized patients with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-8201a</intervention_name>
    <description>DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.</description>
    <arm_group_label>Exploratory: Naïve HER2 IHC 1+</arm_group_label>
    <arm_group_label>Exploratory: Naïve HER2 IHC 2+/ISH-</arm_group_label>
    <arm_group_label>Parallel: DS-8201a</arm_group_label>
    <other_name>Experimental product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician's Choice</intervention_name>
    <description>Either:&#xD;
Irinotecan monotherapy (Starting dosage and usage is 150 mg/m2 biweekly, with dose reduction permitted)&#xD;
Paclitaxel monotherapy (Starting dosage and usage is 80 mg/m2 weekly, with dose reduction permitted)</description>
    <arm_group_label>Parallel: Physician's Choice</arm_group_label>
    <other_name>Standard of Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has a pathologically documented locally advanced or metastatic adenocarcinoma of&#xD;
             gastric or gastroesophageal junction&#xD;
&#xD;
          2. Progression on and after at least 2 prior regimens&#xD;
&#xD;
          3. Has an adequate tumor sample&#xD;
&#xD;
          4. Has measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST)&#xD;
             version 1.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a medical history of myocardial infarction, symptomatic congestive heart failure&#xD;
             (CHF) (NYHA classes II-IV), unstable angina or serious cardiac arrhythmia&#xD;
&#xD;
          2. Has a QTc prolongation to &gt; 450 millisecond (ms) in males and &gt; 470 ms in females&#xD;
&#xD;
          3. Has a medical history of clinically significant lung disease&#xD;
&#xD;
          4. Is suspected to have certain other protocol-defined diseases based on imaging at&#xD;
             screening period&#xD;
&#xD;
          5. Has history of any disease, metastatic condition, drug/medication use or other&#xD;
             condition that might, per protocol or in the opinion of the investigator, compromise:&#xD;
&#xD;
               1. safety or well-being of the participant or offspring&#xD;
&#xD;
               2. safety of study staff&#xD;
&#xD;
               3. analysis of results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirosaki University Hospital</name>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <zip>036-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Community Health Care Organization Kyushu Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>806-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center</name>
      <address>
        <city>Ōta</city>
        <state>Gunma</state>
        <zip>373-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kure Medical Center</name>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <zip>737-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibaraki Prefectural Central Hospital</name>
      <address>
        <city>Kasama</city>
        <state>Ibaraki</state>
        <zip>309-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital</name>
      <address>
        <city>Shiwa-gun</city>
        <state>Iwate</state>
        <zip>028-3695</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa University Hospital</name>
      <address>
        <city>Kita</city>
        <state>Kagawa</state>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Kitasato Institute Kitasato University Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Kyoto Daini Hospital</name>
      <address>
        <city>Kamigyō-ku</city>
        <state>Kyoto</state>
        <zip>602-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyagi Cancer Center</name>
      <address>
        <city>Natori</city>
        <state>Miyagi</state>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaki Citizen Hospital</name>
      <address>
        <city>Osaki</city>
        <state>Miyagi</state>
        <zip>989-6183</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyonaka Municipal Hospital</name>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <zip>560-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tochigi Cancer Center</name>
      <address>
        <city>Utsunomiya</city>
        <state>Tochigi</state>
        <zip>320-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Komagome Hospital</name>
      <address>
        <city>Bunkyō-Ku</city>
        <state>Tokyo</state>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of Japanese Foundation for Cancer Research</name>
      <address>
        <city>Koto-Ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Koto Toyosu Hospital</name>
      <address>
        <city>Koto-Ku</city>
        <state>Tokyo</state>
        <zip>135-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Minato-Ku</city>
        <state>Tokyo</state>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center</name>
      <address>
        <city>Chiba</city>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukui Prefectural Hospital</name>
      <address>
        <city>Fukui</city>
        <zip>910-8526</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu University Hospital</name>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Asa Citizens Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>731-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima Prefectural Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kochi Health Sciences Center</name>
      <address>
        <city>Kochi</city>
        <zip>781-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka</city>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Saitama</city>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka General Hospital</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-8527</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungcheongbuk-do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Ilsan</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>48108</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center, Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29.</citation>
    <PMID>32469182</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <results_first_submitted>November 3, 2020</results_first_submitted>
  <results_first_submitted_qc>November 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2020</results_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenocarcinoma Metastatic</keyword>
  <keyword>Adenocarcinoma of the Stomach</keyword>
  <keyword>Adenocarcinoma of the Gastroesophageal Junction</keyword>
  <keyword>HER2 Overexpression</keyword>
  <keyword>Adenocarcinoma, Locally Advanced</keyword>
  <keyword>DESTINY - Gastric 01</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03329690/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In the Primary Cohort, a total of 188 participants who met all inclusion criteria and no exclusion criteria were enrolled and randomized to treatment. In the Exploratory Cohorts, a total of 45 non-randomized participants were enrolled and 44 patients received treatment. Study participants for all cohorts were enrolled at clinic sites in South Korea and Japan.</recruitment_details>
      <pre_assignment_details>In the Primary Cohort, participants with HER2 overexpressing gastric of GEJ adenocarcinoma were randomized (2:1) to either DS-8201a or physician's choice (irinotecan or paclitaxel). In the Exploratory Cohorts, participants with HER2 IHC 2+/ISH negative advanced gastric or GEJ adenocarcinoma who were naïve to HER2 treatment received DS-8201a.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DS-8201a</title>
          <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Physician's Choice Irinotecan</title>
          <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
        </group>
        <group group_id="P3">
          <title>Physician's Choice Paclitaxel</title>
          <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
        </group>
        <group group_id="P4">
          <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
          <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
        </group>
        <group group_id="P5">
          <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
          <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease per RECIST</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical progression</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline and demographic characteristics were assessed in the Full Analysis Set.</population>
      <group_list>
        <group group_id="B1">
          <title>DS-8201a</title>
          <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Physician's Choice Irinotecan</title>
          <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
        </group>
        <group group_id="B3">
          <title>Physician's Choice Paclitaxel</title>
          <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
        </group>
        <group group_id="B4">
          <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
          <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
        </group>
        <group group_id="B5">
          <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
          <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="24"/>
            <count group_id="B6" value="231"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="10.36"/>
                    <measurement group_id="B2" value="64.9" spread="10.54"/>
                    <measurement group_id="B3" value="63.4" spread="8.96"/>
                    <measurement group_id="B4" value="62.5" spread="10.87"/>
                    <measurement group_id="B5" value="55.5" spread="12.12"/>
                    <measurement group_id="B6" value="63.3" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Objective Response Rate Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</title>
        <description>The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by independent central imaging review (ICR) based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Unconfirmed ORR (not confirmed by ICR) and confirmed ORR (confirmed by ICR) are reported.</description>
        <time_frame>Baseline to date of first documented objective response (CR or PR), up to 25 months postdose</time_frame>
        <population>Objective response rate was assessed in the Primary Cohort in the Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Physician's Choice Irinotecan</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Physician's Choice Paclitaxel</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O4">
            <title>Physician's Choice Overall</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Objective Response Rate Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</title>
          <description>The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by independent central imaging review (ICR) based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Unconfirmed ORR (not confirmed by ICR) and confirmed ORR (confirmed by ICR) are reported.</description>
          <population>Objective response rate was assessed in the Primary Cohort in the Intent-to-Treat Analysis Set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unconfirmed ORR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed ORR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test with region as a stratification factor</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</title>
        <description>The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by independent central imaging review (ICR) based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Unconfirmed BOR (not confirmed by ICR) and confirmed BOR (confirmed by ICR) are reported.</description>
        <time_frame>Baseline to date of first documented objective response, up to 25 months postdose</time_frame>
        <population>Best overall response was assessed in the Primary Cohort in the Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Physician's Choice Irinotecan</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Physician's Choice Paclitaxel</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O4">
            <title>Physician's Choice Overall</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</title>
          <description>The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by independent central imaging review (ICR) based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Unconfirmed BOR (not confirmed by ICR) and confirmed BOR (confirmed by ICR) are reported.</description>
          <population>Best overall response was assessed in the Primary Cohort in the Intent-to-Treat Analysis Set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unconfirmed Complete response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconfirmed Partial response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconfirmed Stable disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconfirmed Progressive disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconfirmed Not evaluable (NE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Complete response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Partial response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Stable disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Progressive disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Not evaluable (NE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</title>
        <description>Duration of survival follow-up (months) was defined as the date of last contact - date of randomization/ registration + 1.Overall Survival (OS) was defined as the time from the date of randomization (the date of the registration for the Exploratory Cohorts) to the date of death due to any cause.</description>
        <time_frame>From the date of randomization to the date of death (due to any cause), up to 25 months postdose</time_frame>
        <population>Duration of survival and overall survival were assessed in the Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Physician's Choice Irinotecan</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Physician's Choice Paclitaxel</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O4">
            <title>Physician's Choice Overall</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O5">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O6">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</title>
          <description>Duration of survival follow-up (months) was defined as the date of last contact - date of randomization/ registration + 1.Overall Survival (OS) was defined as the time from the date of randomization (the date of the registration for the Exploratory Cohorts) to the date of death due to any cause.</description>
          <population>Duration of survival and overall survival were assessed in the Intent-to-Treat Analysis Set.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration of survival follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="0.4" upper_limit="23.1"/>
                    <measurement group_id="O2" value="7.1" lower_limit="0.3" upper_limit="20.3"/>
                    <measurement group_id="O3" value="5.5" lower_limit="2.0" upper_limit="14.3"/>
                    <measurement group_id="O4" value="7.0" lower_limit="0.3" upper_limit="20.3"/>
                    <measurement group_id="O5" value="7.3" lower_limit="0.2" upper_limit="19.6"/>
                    <measurement group_id="O6" value="8.4" lower_limit="1.8" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="0.4" upper_limit="23.1"/>
                    <measurement group_id="O2" value="8.4" lower_limit="0.3" upper_limit="20.3"/>
                    <measurement group_id="O3" value="14.3" lower_limit="2.0" upper_limit="14.3"/>
                    <measurement group_id="O4" value="8.4" lower_limit="0.3" upper_limit="20.3"/>
                    <measurement group_id="O5" value="7.8" lower_limit="0.2" upper_limit="19.6"/>
                    <measurement group_id="O6" value="8.5" lower_limit="1.8" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</title>
        <description>Progression-free survival (PFS) was defined as the time from the date of randomization (the date of the registration for the Exploratory Cohorts) to the earliest date of the first objective documentation of progressive disease (PD) or death due to any cause. PD was defined as at least a 20% increase in the sum of diameters of target lesions.</description>
        <time_frame>From the date of randomization to the first documented disease progression or date of death (whichever occurs first), up to 25 months postdose</time_frame>
        <population>Progression-free survival (PFS) was assessed in the Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Physician's Choice Irinotecan</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Physician's Choice Paclitaxel</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O4">
            <title>Physician's Choice Overall</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O5">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O6">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</title>
          <description>Progression-free survival (PFS) was defined as the time from the date of randomization (the date of the registration for the Exploratory Cohorts) to the earliest date of the first objective documentation of progressive disease (PD) or death due to any cause. PD was defined as at least a 20% increase in the sum of diameters of target lesions.</description>
          <population>Progression-free survival (PFS) was assessed in the Intent-to-Treat Analysis Set.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="4.3" upper_limit="6.9"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.0" upper_limit="4.3"/>
                    <measurement group_id="O3" value="4.9" lower_limit="2.0" upper_limit="NA">Missing upper limit was not calculable due to right censored data; last timepoint censored and estimate is infinity</measurement>
                    <measurement group_id="O4" value="3.5" lower_limit="2.0" upper_limit="4.3"/>
                    <measurement group_id="O5" value="4.4" lower_limit="2.7" upper_limit="7.1"/>
                    <measurement group_id="O6" value="2.8" lower_limit="1.5" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Full Analysis Set)</title>
        <description>Duration of Response (DOR) was defined as the time from the date of the first documentation of objective response (complete response [CR] or partial response [PR]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR was measured for responding subjects (PR or CR) only.</description>
        <time_frame>From the date of first objective response (CR or PR) to the date of first documentation of PD or death (whichever occurs first), up to 25 months postdose</time_frame>
        <population>Duration of response (DOR) was assessed in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Physician's Choice Irinotecan</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Physician's Choice Paclitaxel</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O4">
            <title>Physician's Choice Overall</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O5">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O6">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Full Analysis Set)</title>
          <description>Duration of Response (DOR) was defined as the time from the date of the first documentation of objective response (complete response [CR] or partial response [PR]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR was measured for responding subjects (PR or CR) only.</description>
          <population>Duration of response (DOR) was assessed in the Full Analysis Set.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unconfirmed Duration of response (DOR)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="0" upper_limit="21"/>
                    <measurement group_id="O2" value="4.1" lower_limit="0" upper_limit="4.9"/>
                    <measurement group_id="O3" value="3.9" lower_limit="3.9" upper_limit="3.9"/>
                    <measurement group_id="O4" value="3.9" lower_limit="0" upper_limit="4.9"/>
                    <measurement group_id="O5" value="6.8" lower_limit="1.4" upper_limit="9.7"/>
                    <measurement group_id="O6" value="7.1" lower_limit="1.4" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Duration of response (DOR)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="1.4" upper_limit="21.0"/>
                    <measurement group_id="O2" value="4.1" lower_limit="1.4" upper_limit="4.9"/>
                    <measurement group_id="O3" value="3.9" lower_limit="3.9" upper_limit="3.9"/>
                    <measurement group_id="O4" value="3.9" lower_limit="1.4" upper_limit="4.9"/>
                    <measurement group_id="O5" value="7.6" lower_limit="2.4" upper_limit="9.7"/>
                    <measurement group_id="O6" value="12.5" lower_limit="8.1" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate With and Without Confirmation by Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</title>
        <description>Disease control rate (DCR) was defined as the sum of complete response (CR) rate, partial response (PR) rate, and stable disease (SD) rate. As per RECIST v1.1, CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.</description>
        <time_frame>Baseline to date of first documented objective response (CR, PR, and SD), up to 25 months postdose</time_frame>
        <population>Disease control rate (DCR) was assessed in the Intent-to-Treat Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Physician's Choice Irinotecan</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Physician's Choice Paclitaxel</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O4">
            <title>Physician's Choice Overall</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O5">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O6">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate With and Without Confirmation by Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</title>
          <description>Disease control rate (DCR) was defined as the sum of complete response (CR) rate, partial response (PR) rate, and stable disease (SD) rate. As per RECIST v1.1, CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.</description>
          <population>Disease control rate (DCR) was assessed in the Intent-to-Treat Set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate and Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</title>
        <description>The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Independent Central Review (ICR) based on RECIST version 1.1. The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by Investigator based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions). Confirmed ORR and BOR (confirmed by ICR) are reported.</description>
        <time_frame>From randomization to first documented objective response, up to 25 months postdose</time_frame>
        <population>Best overall response was assessed in the Exploratory Cohorts in the Intent-to-Treat Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate and Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)</title>
          <description>The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Independent Central Review (ICR) based on RECIST version 1.1. The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by Investigator based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions). Confirmed ORR and BOR (confirmed by ICR) are reported.</description>
          <population>Best overall response was assessed in the Exploratory Cohorts in the Intent-to-Treat Analysis Set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confirmed Objective response rate (ORR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Complete response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Partial response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Stable disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Progressive disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inevaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Full Analysis Set)</title>
        <description>Time to treatment failure (TTF) was defined as the time from the date of randomization (the date of the registration for Exploratory Cohorts) to the earliest date of the first objective documentation of progressive disease (PD), death due to any cause, or treatment discontinuation.</description>
        <time_frame>From date of randomization to first documentation of PD, death due to any cause, or treatment discontinuation (whichever comes first), up to 25 months postdose</time_frame>
        <population>Time to treatment failure (TTF) was assessed in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Physician's Choice Irinotecan</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Physician's Choice Paclitaxel</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O4">
            <title>Physician's Choice Overall</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O5">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O6">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Full Analysis Set)</title>
          <description>Time to treatment failure (TTF) was defined as the time from the date of randomization (the date of the registration for Exploratory Cohorts) to the earliest date of the first objective documentation of progressive disease (PD), death due to any cause, or treatment discontinuation.</description>
          <population>Time to treatment failure (TTF) was assessed in the Full Analysis Set.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.9" upper_limit="5.1"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.6" upper_limit="2.8"/>
                    <measurement group_id="O3" value="2.9" lower_limit="1.1" upper_limit="6.8"/>
                    <measurement group_id="O4" value="2.6" lower_limit="1.6" upper_limit="2.8"/>
                    <measurement group_id="O5" value="3.7" lower_limit="1.7" upper_limit="5.5"/>
                    <measurement group_id="O6" value="2.2" lower_limit="1.4" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate and Best Overall Response Based on Investigator Assessment Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Response Evaluable Set)</title>
        <description>The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Investigator based on RECIST version 1.1. The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by Investigator based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions). Unconfirmed ORR and BOR (not confirmed by Investigator) and confirmed ORR and BOR (confirmed by Investigator) are reported.</description>
        <time_frame>From randomization to first documented objective response, up to 25 months postdose</time_frame>
        <population>Objective response rate (ORR) and best overall response (BOR) were assessed in the Response Evaluable Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Physician's Choice Irinotecan</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Physician's Choice Paclitaxel</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O4">
            <title>Physician's Choice Overall</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O5">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O6">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate and Best Overall Response Based on Investigator Assessment Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Response Evaluable Set)</title>
          <description>The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Investigator based on RECIST version 1.1. The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by Investigator based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions). Unconfirmed ORR and BOR (not confirmed by Investigator) and confirmed ORR and BOR (confirmed by Investigator) are reported.</description>
          <population>Objective response rate (ORR) and best overall response (BOR) were assessed in the Response Evaluable Set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unconfirmed Objective response rate (ORR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconfirmed Complete response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconfirmed Partial response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconfirmed Stable disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconfirmed Progressive disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconfirmed Not evaluable (NE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Objective response rate (ORR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Complete response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Partial response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Stable disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Progressive disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed Not evaluable (NE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter of Maximum Observed Serum Concentration (Cmax) and Trough Serum Concentration (Ctrough) of DS-8201a, Total Anti-HER2 Antibody, and MAAA-1181 Following Treatment With DS-8201a</title>
        <description>Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. The maximum serum concentration (Cmax) and the trough serum concentration (Ctrough) of DS-8201a were assessed. These serum PK parameters for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.</description>
        <time_frame>Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)</time_frame>
        <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O3">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter of Maximum Observed Serum Concentration (Cmax) and Trough Serum Concentration (Ctrough) of DS-8201a, Total Anti-HER2 Antibody, and MAAA-1181 Following Treatment With DS-8201a</title>
          <description>Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. The maximum serum concentration (Cmax) and the trough serum concentration (Ctrough) of DS-8201a were assessed. These serum PK parameters for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.</description>
          <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax: DS-8201a, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" spread="28.4"/>
                    <measurement group_id="O2" value="119" spread="29.1"/>
                    <measurement group_id="O3" value="127" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax: DS-8201a, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137" spread="31.1"/>
                    <measurement group_id="O2" value="128" spread="25.6"/>
                    <measurement group_id="O3" value="123" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax: Total Anti-HER2 antibody, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" spread="30.6"/>
                    <measurement group_id="O2" value="105" spread="26.1"/>
                    <measurement group_id="O3" value="110" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax: Total Anti-HER2 antibody, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121" spread="28.4"/>
                    <measurement group_id="O2" value="115" spread="24.2"/>
                    <measurement group_id="O3" value="112" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax: MAAA-1181a, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="4.79"/>
                    <measurement group_id="O2" value="13.3" spread="8.52"/>
                    <measurement group_id="O3" value="13.3" spread="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax: MAAA-1181a, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.08" spread="3.81"/>
                    <measurement group_id="O2" value="7.62" spread="1.86"/>
                    <measurement group_id="O3" value="9.83" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough: DS-8201a, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" spread="3.08"/>
                    <measurement group_id="O2" value="4.52" spread="2.42"/>
                    <measurement group_id="O3" value="9.51" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough: DS-8201a, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="17.3"/>
                    <measurement group_id="O2" value="8.84" spread="3.09"/>
                    <measurement group_id="O3" value="13.2" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough: Total Anti-HER2 antibody, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.56" spread="8.60"/>
                    <measurement group_id="O2" value="5.33" spread="2.97"/>
                    <measurement group_id="O3" value="10.0" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough: Total Anti-HER2 antibody, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="13.6"/>
                    <measurement group_id="O2" value="12.2" spread="5.76"/>
                    <measurement group_id="O3" value="14.6" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough: MAAA-1181a, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.316" spread="0.294"/>
                    <measurement group_id="O2" value="0.290" spread="0.237"/>
                    <measurement group_id="O3" value="0.772" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough: MAAA-1181a, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.714" spread="2.19"/>
                    <measurement group_id="O2" value="0.378" spread="0.138"/>
                    <measurement group_id="O3" value="1.10" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of Area Under the Concentration Versus-Time Curve of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a</title>
        <description>Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. Area under the concentration versus time curve (AUC) from Time 0 to the Last Quantifiable Concentration (AUClast) and Area Under the Concentration versus-Time Curve up to 21 days (AUC21d) are reported. These serum PK parameters for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.</description>
        <time_frame>Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)</time_frame>
        <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O3">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of Area Under the Concentration Versus-Time Curve of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a</title>
          <description>Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. Area under the concentration versus time curve (AUC) from Time 0 to the Last Quantifiable Concentration (AUClast) and Area Under the Concentration versus-Time Curve up to 21 days (AUC21d) are reported. These serum PK parameters for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.</description>
          <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
          <units>ug*d/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUClast: DS-8201a, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="611" spread="150"/>
                    <measurement group_id="O2" value="572" spread="143"/>
                    <measurement group_id="O3" value="545" spread="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUClast: DS-8201a, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>AUClast: Total Anti-HER2 antibody, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="667" spread="241"/>
                    <measurement group_id="O2" value="570" spread="126"/>
                    <measurement group_id="O3" value="547" spread="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUClast: Total Anti-HER2 antibody, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>AUClast: MAAA-1181a, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" spread="16.3"/>
                    <measurement group_id="O2" value="53.4" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUClast: MAAA-1181a, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>AUC21d: DS-8201a, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="612" spread="150"/>
                    <measurement group_id="O2" value="572" spread="143"/>
                    <measurement group_id="O3" value="569" spread="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC21d: DS-8201a, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="867" spread="213"/>
                    <measurement group_id="O2" value="746" spread="197"/>
                    <measurement group_id="O3" value="724" spread="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC21d: Total Anti-HER2 antibody, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="651" spread="210"/>
                    <measurement group_id="O2" value="570" spread="126"/>
                    <measurement group_id="O3" value="582" spread="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC21d: Total Anti-HER2 antibody, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="888" spread="244"/>
                    <measurement group_id="O2" value="775" spread="210"/>
                    <measurement group_id="O3" value="737" spread="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC21d: MAAA-1181a, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" spread="16.1"/>
                    <measurement group_id="O2" value="44.9" spread="20.1"/>
                    <measurement group_id="O3" value="44.5" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC21d: MAAA-1181a, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" spread="15.1"/>
                    <measurement group_id="O2" value="39.4" spread="8.36"/>
                    <measurement group_id="O3" value="44.6" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter of Time to Maximum Serum Concentration (Tmax) of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a</title>
        <description>Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. The time to maximum serum concentration (Tmax) of DS-8201a was assessed. This serum PK parameter for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.</description>
        <time_frame>Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)</time_frame>
        <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O3">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter of Time to Maximum Serum Concentration (Tmax) of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a</title>
          <description>Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. The time to maximum serum concentration (Tmax) of DS-8201a was assessed. This serum PK parameter for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.</description>
          <population>Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DS-8201a, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" lower_limit="0" upper_limit="7.15"/>
                    <measurement group_id="O2" value="3.90" lower_limit="1.58" upper_limit="7.12"/>
                    <measurement group_id="O3" value="3.89" lower_limit="1.53" upper_limit="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DS-8201a, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="0.58" upper_limit="7.25"/>
                    <measurement group_id="O2" value="4.00" lower_limit="0.58" upper_limit="6.82"/>
                    <measurement group_id="O3" value="4.00" lower_limit="0.68" upper_limit="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Anti-HER2 antibody, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" lower_limit="0" upper_limit="7.15"/>
                    <measurement group_id="O2" value="3.83" lower_limit="1.58" upper_limit="7.08"/>
                    <measurement group_id="O3" value="3.87" lower_limit="1.53" upper_limit="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Anti-HER2 antibody, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" lower_limit="0.53" upper_limit="7.17"/>
                    <measurement group_id="O2" value="4.00" lower_limit="0.57" upper_limit="6.83"/>
                    <measurement group_id="O3" value="3.75" lower_limit="0.53" upper_limit="7.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAAA-1181a, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" lower_limit="3.75" upper_limit="7.25"/>
                    <measurement group_id="O2" value="6.83" lower_limit="3.83" upper_limit="141.73"/>
                    <measurement group_id="O3" value="6.81" lower_limit="3.83" upper_limit="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAAA-1181a, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.80" lower_limit="3.78" upper_limit="7.25"/>
                    <measurement group_id="O2" value="6.82" lower_limit="3.88" upper_limit="7.10"/>
                    <measurement group_id="O3" value="6.77" lower_limit="3.98" upper_limit="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter Terminal Elimination Half-life (t1/2) of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a</title>
        <description>Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. Terminal elimination half-life (t1/2) of DS-8201a was assessed. This serum PK parameter for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.</description>
        <time_frame>Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)</time_frame>
        <population>Pharmacokinetic parameters were assessed in patients with available data in the Pharmacokinetic Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O3">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter Terminal Elimination Half-life (t1/2) of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a</title>
          <description>Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. Terminal elimination half-life (t1/2) of DS-8201a was assessed. This serum PK parameter for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods.</description>
          <population>Pharmacokinetic parameters were assessed in patients with available data in the Pharmacokinetic Analysis Set.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DS-8201a, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.77" spread="1.37"/>
                    <measurement group_id="O2" value="5.54" spread="1.08"/>
                    <measurement group_id="O3" value="5.52" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DS-8201a, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.46" spread="1.82"/>
                    <measurement group_id="O2" value="6.40" spread="1.00"/>
                    <measurement group_id="O3" value="6.35" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Anti-HER2 antibody, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.20" spread="2.22"/>
                    <measurement group_id="O2" value="5.54" spread="1.01"/>
                    <measurement group_id="O3" value="5.65" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Anti-HER2 antibody, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="2.04"/>
                    <measurement group_id="O2" value="7.90" spread="2.10"/>
                    <measurement group_id="O3" value="6.17" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAAA-1181a, Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="1.11"/>
                    <measurement group_id="O2" value="5.21" spread="0.939"/>
                    <measurement group_id="O3" value="5.61" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAAA-1181a, Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.01" spread="1.65"/>
                    <measurement group_id="O2" value="6.18" spread="1.02"/>
                    <measurement group_id="O3" value="5.80" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Summary of Treatment-emergent Adverse Events (TEAEs) Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (Safety Analysis Set)</title>
        <description>A treatment-emergent adverse event (TEAE) is defined as an adverse event that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the initiating the study drug until 47 days after last dose of the study drug. Serious adverse events (SAEs) with an onset or worsening 48 days or more after the last dose of study drug, if considered related to the study treatment, are also TEAEs.</description>
        <time_frame>Baseline up to 47 days after last dose, up to 25 months postdose</time_frame>
        <population>Adverse events were assessed in the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Physician's Choice Irinotecan</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Physician's Choice Paclitaxel</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O4">
            <title>Physician's Choice Overall</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O5">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O6">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Summary of Treatment-emergent Adverse Events (TEAEs) Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (Safety Analysis Set)</title>
          <description>A treatment-emergent adverse event (TEAE) is defined as an adverse event that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the initiating the study drug until 47 days after last dose of the study drug. Serious adverse events (SAEs) with an onset or worsening 48 days or more after the last dose of study drug, if considered related to the study treatment, are also TEAEs.</description>
          <population>Adverse events were assessed in the Safety Analysis Set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs associated with drug withdrawn</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs associated with drug withdrawn</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs associated with dose reduced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs associated with dose reduced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs associated with drug interrupted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAE associated with drug interrupted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs associated with death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Most Common Treatment-Emergent Adverse Events (TEAEs) ≥20% of Any Grade by Preferred Term Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Safety Analysis Set)</title>
        <description>A treatment-emergent adverse event (TEAE) is defined as an adverse event that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the initiating the study drug until 47 days after last dose of the study drug.</description>
        <time_frame>Baseline up to 47 days after last dose, up to 25 months postdose</time_frame>
        <population>Adverse events were assessed in the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8201a</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Physician's Choice Irinotecan</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Physician's Choice Paclitaxel</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O4">
            <title>Physician's Choice Overall</title>
            <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
          </group>
          <group group_id="O5">
            <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
          </group>
          <group group_id="O6">
            <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
            <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Most Common Treatment-Emergent Adverse Events (TEAEs) ≥20% of Any Grade by Preferred Term Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Safety Analysis Set)</title>
          <description>A treatment-emergent adverse event (TEAE) is defined as an adverse event that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the initiating the study drug until 47 days after last dose of the study drug.</description>
          <population>Adverse events were assessed in the Safety Analysis Set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophil count decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte count decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoalbuminaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oedema peripheral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysgeusia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral sensory neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse event (TEAE) data were collected from baseline up to 47 days after last dose, up to 25 months postdose.</time_frame>
      <desc>A TEAE is defined as an adverse event (AE) that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the initiating the study drug until 47 days after last dose of the study drug. Serious adverse events (SAEs) with an onset or worsening 48 days or more after the last dose of study drug, if considered related to the study treatment, are also TEAEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>DS-8201a</title>
          <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Physician's Choice Irinotecan</title>
          <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.</description>
        </group>
        <group group_id="E3">
          <title>Physician's Choice Paclitaxel</title>
          <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
        </group>
        <group group_id="E4">
          <title>Physician's Choice Overall</title>
          <description>Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.</description>
        </group>
        <group group_id="E5">
          <title>Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a</title>
          <description>Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.</description>
        </group>
        <group group_id="E6">
          <title>Exploratory: Naïve HER2 IHC 1+, DS-8201a</title>
          <description>Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Device-related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cholangitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pericarditis malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Corneal erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Influenza-like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cholinergic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Contact for Clinical Trial Information</name_or_title>
      <organization>Daiichi Sankyo</organization>
      <phone>908-992-6400</phone>
      <email>CTRinfo@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

